These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22465172)

  • 21. Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.
    Lahiri DK; Alley GM; Tweedie D; Chen D; Greig NH
    Neuromolecular Med; 2007; 9(2):157-68. PubMed ID: 17627035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
    Martinez A; Castro A
    Expert Opin Investig Drugs; 2006 Jan; 15(1):1-12. PubMed ID: 16370929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational and Kinetic Studies of Acetylcholine Esterase Inhibition by Phenserine.
    Tabrez S; Damanhouri GA
    Curr Pharm Des; 2019; 25(18):2108-2112. PubMed ID: 31258059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
    Nordberg A; Kadir A; Andreasen N; Almkvist O; Wall A; Långström B; Zetterberg H
    J Alzheimers Dis; 2015; 47(3):691-704. PubMed ID: 26401704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
    Sahoo AK; Dandapat J; Dash UC; Kanhar S
    J Ethnopharmacol; 2018 Apr; 215():42-73. PubMed ID: 29248451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine.
    Marutle A; Ohmitsu M; Nilbratt M; Greig NH; Nordberg A; Sugaya K
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12506-11. PubMed ID: 17640880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.
    Iijima S; Greig NH; Garofalo P; Spangler EL; Heller B; Brossi A; Ingram DK
    Psychopharmacology (Berl); 1993; 112(4):415-20. PubMed ID: 7871051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing the success rate for Alzheimer's disease drug discovery and development.
    Becker RE; Greig NH
    Expert Opin Drug Discov; 2012 Apr; 7(4):367-70. PubMed ID: 22439785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide.
    Utsuki T; Yu QS; Davidson D; Chen D; Holloway HW; Brossi A; Sambamurti K; Lahiri DK; Greig NH; Giordano T
    J Pharmacol Exp Ther; 2006 Aug; 318(2):855-62. PubMed ID: 16690718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.
    Becker RE; Greig NH
    Curr Alzheimer Res; 2008 Aug; 5(4):346-57. PubMed ID: 18690832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice.
    Lecca D; Bader M; Tweedie D; Hoffman AF; Jung YJ; Hsueh SC; Hoffer BJ; Becker RE; Pick CG; Lupica CR; Greig NH
    Neurobiol Dis; 2019 Oct; 130():104528. PubMed ID: 31295555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
    Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
    J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
    Musiał A; Bajda M; Malawska B
    Curr Med Chem; 2007; 14(25):2654-79. PubMed ID: 17979717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.
    Cutler NR; Sramek JJ
    Eur J Clin Pharmacol; 1995; 48(6):421-8. PubMed ID: 8582458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms.
    Tweedie D; Fukui K; Li Y; Yu QS; Barak S; Tamargo IA; Rubovitch V; Holloway HW; Lehrmann E; Wood WH; Zhang Y; Becker KG; Perez E; Van Praag H; Luo Y; Hoffer BJ; Becker RE; Pick CG; Greig NH
    PLoS One; 2016; 11(6):e0156493. PubMed ID: 27254111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health.
    Bentley P; Driver J; Dolan RJ
    Brain; 2008 Feb; 131(Pt 2):409-24. PubMed ID: 18077465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
    Imbimbo BP; Martelli P; Troetel WM; Lucchelli F; Lucca U; Thal LJ
    Neurology; 1999 Mar; 52(4):700-8. PubMed ID: 10078713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.